Cogent Biosciences, Inc. (COGT)

7,60 -0,16 (-2,06%) Alla chiusura: 04:00PM EDT

Cogent Biosciences, Inc.

275 Wyman Street
3rd Floor
Waltham, MA 02451
United States
617 945 5576
https://www.cogentbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 164

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Andrew R. Robbins M.B.A.	President, CEO & Director	1,06M	N/D	1976
Dr. John Edward Robinson Ph.D.	Chief Scientific Officer	749,89k	N/D	1975
Dr. Jessica Sachs M.D.	Chief Medical Officer	773,92k	N/D	1975
Mr. John L. Green C.A., CPA	CFO & Principal Accounting Officer	763,99k	N/D	1980
Mr. Brad Barnett	Chief Technology Officer	N/D	N/D	N/D
Christi Waarich	Senior Director of Investor Relations	N/D	N/D	N/D
Mr. Evan D. Kearns J.D.	Chief Legal Officer & Corporate Secretary	N/D	N/D	1980
Ms. Erin Schellhammer	Chief People Officer	N/D	N/D	N/D
Mr. Dana R. Martin Pharm.D.	Senior VP of Medical Affairs & Chief Patient Officer	N/D	N/D	N/D
Brad Fell	Senior Vice President of Chemistry	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Cogent Biosciences, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.